MANGOCEUTICALS, INC. Reports Unregistered Equity Sales
Ticker: MGRX · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $7,500, $0.2877, $43,155, $6,250 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, unregistered-securities
TL;DR
Mangoceuticals sold unregistered stock on 8/15. Dilution alert?
AI Summary
On August 15, 2024, MANGOCEUTICALS, INC. reported unregistered sales of equity securities. The filing does not disclose specific details regarding the number of shares sold, the price per share, or the total dollar amount of the transaction.
Why It Matters
This filing indicates MANGOCEUTICALS, INC. has issued equity outside of a public offering, which could impact existing shareholders through dilution.
Risk Assessment
Risk Level: medium — Unregistered sales can sometimes signal financial distress or a need for capital, and may lead to dilution for existing shareholders.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- August 15, 2024 (date) — Date of Earliest Event Reported
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type of securities.
How many shares were sold in this unregistered offering?
The filing does not provide the number of shares sold.
What was the total dollar amount of the unregistered equity sale?
The filing does not disclose the total dollar amount of the transaction.
Were these securities sold to accredited investors?
The filing mentions 'Unregistered Sales of Equity Securities' but does not specify the nature of the purchasers or if they were accredited investors.
What is the purpose of this unregistered sale of equity securities?
The filing does not state the specific purpose for the unregistered sale of equity securities.
Filing Stats: 1,688 words · 7 min read · ~6 pages · Grade level 14.6 · Accepted 2024-10-02 17:25:10
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $7,500 — pon issuance) and agreed to pay Veritas $7,500 per month in cash. The shares were valu
- $0.2877 — onth in cash. The shares were valued at $0.2877 per share for a total of $43,155. On
- $43,155 — ued at $0.2877 per share for a total of $43,155. On August 22, 2024, we entered into
- $6,250 — e twelve months, and agreed to pay Levo $6,250 per month in cash. The shares were valu
- $56,102 — ued at $0.2877 per share for a total of $56,102. The Company also agreed to grant Lev
- $30,000 — d upon issuance) and agreed to pay Luca $30,000 in cash, payable as follows: (a) $5,000
- $5,000 — 30,000 in cash, payable as follows: (a) $5,000 on the signing of the agreement; and (b
- $0.27 — tain matters. The shares were valued at $0.27 per share for a total of $175,500. As
- $175,500 — alued at $0.27 per share for a total of $175,500. As previously disclosed in the Curre
- $25,000,000 — int Capital committed to purchase up to $25,000,000 of the Company's common stock pursuant
- $0.26 — k pursuant to the terms of the ELOC for $0.26 per share for a total of $521,016, net
- $521,016 — ELOC for $0.26 per share for a total of $521,016, net of fees, discounts and expenses.
- $0.2143 — ferred Stock. The shares were valued at $0.2143 per share for a total value of $154,000
- $154,000 — $0.2143 per share for a total value of $154,000. On October 2, 2024, Platinum Point C
Filing Documents
- form8-k.htm (8-K) — 47KB
- 0001493152-24-039223.txt ( ) — 223KB
- mgrx-20240815.xsd (EX-101.SCH) — 3KB
- mgrx-20240815_lab.xml (EX-101.LAB) — 33KB
- mgrx-20240815_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: October 2, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer